Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This commentary reviews the post-Finasteride syndrome and argues that while the condition's validity is debated, comprehensive guidelines are needed to address related risks and treatment options; it reports no new clinical results.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This study found that finasteride use for androgenetic alopecia was not associated with increased sexual dysfunction compared to an age-matched control group.

This study found that finasteride has selective effects on oxidative stress and acetylcholinesterase activity in different brain regions in rats with thioacetamide-induced hepatic encephalopathy.

This study found that finasteride-containing anionic liposomes enhanced skin retention and had moderate hair growth efficacy, suggesting potential for treating androgenetic alopecia with reduced systemic side effects.

This study found that forming solid dispersions and inclusion complexes of finasteride significantly increased its solubility compared to its pure form.

This article reviews multiple entries on the Androlog blog regarding finasteride use, concluding that a 1-mg dose does not adversely affect spermatogenesis or pose a risk during conception or pregnancy.

Finasteride helps reduce pain and inflammation in animals.

Validated method reliably measures finasteride in tablets using liquid chromatography.

In this case report, the authors suggest an association between prolonged finasteride use and anterior subcapsular cataracts, as observed in a 43-year-old man, marking the first reported instance.

This study reports that long-term use of finasteride does not affect bone mineral density in men with benign prostatic hyperplasia over a four-year period.

This review discusses various chromatographic methods for analyzing finasteride in biological fluids and provides no clinical findings, focusing on detection techniques for different concentration levels.

Finasteride increases hair growth, prolongs hair cycle, and lowers dihydrotestosterone levels.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study found that a chitosan-decorated finasteride nanosystem exhibited satisfactory drug release and retention in rat skin, suggesting it could enhance topical delivery for androgenic alopecia treatment.

This study found that resveratrol significantly alleviated testicular damage in male rats caused by finasteride, which otherwise led to decreased testosterone levels and various histopathological alterations in the testes.

This study found that finasteride treatment in male rats altered steroid hormone homeostasis and caused kidney damage, suggesting potential risks for patients with renal dysfunction on androgen or antiandrogen therapy.

This study reports that chemically induced short anogenital distance in male rat fetuses involved distinctive transcriptional changes, suggesting roles for estrogen and Wnt2 signaling in anogenital tissue development.

In this study, finasteride was found to enhance stem cell properties in dermal papilla cells, suggesting potential benefits for hair loss management and regenerative therapies.

This study suggests that the MAPK/ERK signaling pathway plays a role in the regulation of cell proliferation, apoptosis, and cycling in rat urethral plate fibroblasts affected by finasteride-induced hypospadias.

This case report describes a 52-year-old man who developed generalized vitiligo two months after stopping finasteride and suggests this may be part of post-finasteride syndrome.

In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.

This correspondence critiques a previous report advocating finasteride for frontal fibrosing alopecia, arguing that the evidence on its safety and effectiveness is inconclusive, particularly due to methodological limitations.

This study found that paternal exposure to finasteride in male rats may impair fertility and affect androgen-sensitive spermatogenesis in their male offspring.

In this study, no statistically significant association was found between finasteride use and the risk of acute pancreatitis in Taiwanese males aged 40-84.

Finasteride's polymorphic form affects capsule quality and drug effect, requiring strict control.

This review examines reports of prolonged sexual dysfunction and depression associated with finasteride for male pattern hair loss, concluding that significant biases exist and further rigorous trials are needed to assess risks.

This study found that altering neurosteroid levels during early development in male rats can influence KCC2 levels, underscoring the role of neurosteroids in hippocampal maturation.

In this study, 1.25 mg daily finasteride for 28 weeks showed minimal increase in hair density and thickness in normoandrogenic female pattern hair loss, but no significant clinical improvement was observed.

Finasteride caused blisters on hands and feet.